Contact: info@alspinc.com
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
vvvNeurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
44M people world wide
...are living with neurodegenerative disease and the impact is more than doubled when care givers and family members are included.

44M people world wide


-
...TBI increases risk of dementia by as much as two-fold
  
44M people world wide
44M People World Wide

...are living with neurodegenerative disease and the impact is more than doubled when care givers and family members are included...

Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 

 

News & Events 2010


December 1-4, 2010: Dr. Greg Hook of ALSP Inc. and his colleagues Dr. Vivian Hook of UCSD and Dr. Mark Kindy of the Medical University of South Carolina, present three papers at Cold Spring Harbor Laboratory 2010 Meeting on NEURODEGENERATIVE DISEASES: BIOLOGY & THERAPEUTICS


 >Pharmacogenetic features of inhibitors to cathepsin B that improve memory deficit and reduce beta-amyloid related to Alzheimer's Disease by Hook, V. Y. H. and Kindy, M. and Funkelstein, L. and Hook, G. 


>Cathepsin B inhibition reduces brain beta-amyloid peptides while increasing brain BACE1 activity in animal models expressing APP with the normal beta-secretase site sequence by Hook, G. and Hook, V. Y. H. and Kindy, M. 


>Roles of BACE-1 and Cathepsin B in the generation of Abeta peptide in Alzheimer's Disease by Hook, V. Y. H. and Hook, G. and Kindy, M. et al


November 13-17, 2010: Dr. Greg Hook of ALSP Inc. and his colleagues Dr. Vivian Hook of UCSD and Dr. Mark Kindy of the Medical University of South Carolina, present three papers at NEUROSCIENCE 2010 in San Diego


>Roles  of BACE-1 and Cathepsin B in the generation of Abeta peptide in Alzheimer's Disease by Kindy, M. S. and Hook, V. Y. H. and Hook, G. et al.


>Oral administration of cathepsin B inhibitor reduces brain Abeta in guinea pigs by Hook, G. and Kindy, M. 


November 9, 2010: ALSP Inc. receives funding from federal program, Therapeutic Discovery Project Read More...


May 24, 2010: Alzheimer's Drug Discovery Foundation funds ALSP Inc. to move novel therapeutic towards clinic Read More...


< Back